Crizotinib
- Generic Name
- Crizotinib
- Brand Names
- Xalkori
- Drug Type
- Small Molecule
- Chemical Formula
- C21H22Cl2FN5O
- CAS Number
- 877399-52-5
- Unique Ingredient Identifier
- 53AH36668S
- Background
Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusio...
- Indication
Crizotinib is a kinase inhibitor indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK) or ROS1-positive as detected by an FDA-approved test. Crizotinib is also indicated for the treatment of relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is ALK...
- Associated Conditions
- Metastatic Non-Small Cell Lung Cancer, Refractory Anaplastic Large Cell Lymphoma, Recurrent Inflammatory Myofibroblastic Tumors, Refractory Inflammatory Myofibroblastic Tumors, Relapsed Anaplastic Large Cell Lymphoma, Unresectable Inflammatory Myofibroblastic Tumors
- Associated Therapies
- -
Combination Checkpoint Inhibitor Plus Erlotinib or Crizotinib for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-11-28
- Last Posted Date
- 2018-04-02
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 14
- Registration Number
- NCT01998126
- Locations
- 🇺🇸
Huntsman Cancer Institute, Salt Lake City, Utah, United States
Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2013-11-08
- Last Posted Date
- 2024-04-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 137
- Registration Number
- NCT01979536
- Locations
- 🇺🇸
Nationwide Children's Hospital, Columbus, Ohio, United States
🇺🇸Valley Children's Hospital, Madera, California, United States
🇺🇸Naval Medical Center - Portsmouth, Portsmouth, Virginia, United States
A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations
- Conditions
- Interventions
- First Posted Date
- 2013-10-28
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 364
- Registration Number
- NCT01970865
- Locations
- 🇺🇸
Karmanos Center Institute, Detroit, Michigan, United States
🇺🇸University of Colorado Cancer Center, Aurora, Colorado, United States
🇺🇸Highlands Oncology Group/Research, Fayetteville, Arkansas, United States
Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC
- Conditions
- Interventions
- First Posted Date
- 2013-09-18
- Last Posted Date
- 2021-02-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 129
- Registration Number
- NCT01945021
- Locations
- 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan
🇨🇳Taipei Veterans General Hospital, Taipei, Taiwan
🇨🇳National Cheng Kung University Hospital, Tainan, Taiwan
Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
- First Posted Date
- 2013-04-02
- Last Posted Date
- 2019-08-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 59
- Registration Number
- NCT01822496
- Locations
- 🇺🇸
Lahey Hospital and Medical Center, Burlington, Massachusetts, United States
🇺🇸University of Illinois, Chicago, Illinois, United States
🇺🇸Baptist Medical Center South, Jacksonville, Florida, United States
Dasatinib and Crizotinib in Advanced Cancer
- First Posted Date
- 2012-12-07
- Last Posted Date
- 2023-06-07
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 62
- Registration Number
- NCT01744652
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib
- Conditions
- Interventions
- First Posted Date
- 2012-10-23
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Astex Pharmaceuticals, Inc.
- Target Recruit Count
- 220
- Registration Number
- NCT01712217
- Locations
- 🇺🇸
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸UCLA Medical Center, Los Angeles, California, United States
🇺🇸Northwestern University The Feinberg School of Medicine, Chicago, Illinois, United States
Study of the Combination of Crizotinib and Dasatinib in Pediatric Research Participants With Diffuse Pontine Glioma (DIPG) and High-Grade Glioma (HGG)
- Conditions
- Interventions
- First Posted Date
- 2012-07-19
- Last Posted Date
- 2019-03-22
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 36
- Registration Number
- NCT01644773
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
A Study Of Crizotinib Versus Chemotherapy In Previously Untreated ALK Positive East Asian Non-Small Cell Lung Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2012-07-12
- Last Posted Date
- 2020-12-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 207
- Registration Number
- NCT01639001
- Locations
- 🇨🇳
Chang Gung Medical Foundation, LinKou Branch, Taoyuan, Taiwan
🇨🇳Dept. of Respiration. Peking Union Medical College Hospital, Beijing, Beijing, China
🇨🇳Hunan Provincial Tumor Hospital/Division of Oncology, Changsha, Hunan, China
Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2012-05-28
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 46
- Registration Number
- NCT01606878
- Locations
- 🇺🇸
Riley Hospital for Children, Indianapolis, Indiana, United States
🇺🇸Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
🇺🇸St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.